18 min listen
Bayer’s sweeping executive cuts, Wegovy’s expanding reach
FromBioSpace
ratings:
Length:
17 minutes
Released:
Mar 27, 2024
Format:
Podcast episode
Description
It was another busy week! Bayer reduced its executive suite from 14 to 8 as part of a major restructuring.
Meanwhile, the government announced it will pay for Wegovy for patients with heart disease after the Novo Nordisk therapy was approved earlier this month for the cardiovascular indication.
Plus, Mirador’s emergence from stealth and the FDA’s approval of the third therapy for Duchenne muscular dystrophy in less than a year.
Meanwhile, the government announced it will pay for Wegovy for patients with heart disease after the Novo Nordisk therapy was approved earlier this month for the cardiovascular indication.
Plus, Mirador’s emergence from stealth and the FDA’s approval of the third therapy for Duchenne muscular dystrophy in less than a year.
Released:
Mar 27, 2024
Format:
Podcast episode
Titles in the series (46)
Q3 earnings recap: winners, losers & surprises by BioSpace